Trisalus Life Sciences, INC 8-K filings

TriSalus Life Sciences announced Q2 2026 results, with revenue of $11.4 million and maintained full-year guidance of $54-$57 million, despite increased operating losses driven by sales expansion.

TriSalus Life Sciences, Inc. announced the results of its Annual Meeting of Stockholders held on May 14, 2026, including the election of directors and ratification of its independent auditor.

TriSalus Life Sciences reports Q1 2026 results with $8.9M revenue, a $46M equity raise, and revised 2026 revenue guidance.

TriSalus Life Sciences, Inc. reported the upcoming retirement of its Chief of Clinical Operations and the prior appointment of a new Chief Medical Officer.

TriSalus Life Sciences announced the appointment of Dr. Richard Marshall as Chief Medical Officer, effective June 29, 2026, to lead medical strategy and clinical leadership.

TriSalus Life Sciences announced robust fourth quarter and full-year 2025 financial results, exceeding revenue guidance and reaffirming its 2026 outlook, bolstered by a recent $46 million public offering.

TriSalus Life Sciences announced the resignation of Dr. Arjun JJ Desai from its Board of Directors and the immediate appointment of Michael P. Stansky, a seasoned investment management and healthcare expert.

TriSalus Life Sciences announced preliminary Q4 and full-year 2025 revenues exceeding guidance, alongside robust 2026 revenue projections.

TriSalus Life Sciences announced robust third-quarter 2025 financial results, with revenue up 57% year-over-year, and reaffirmed its full-year revenue growth guidance of at least 50%.

Sean Murphy has resigned from the Board of Directors and the Science and Technology Committee of TriSalus Life Sciences, Inc., effective immediately.

TriSalus Life Sciences, Inc. announced a significant increase in its CFO's annual salary and granted performance-based stock options.

TriSalus Life Sciences reports strong Q2 2025 financial results with 52% revenue growth and launches its new TriNav FLX product, reaffirming full-year guidance.

TriSalus Life Sciences successfully completed its exchange offer and consent solicitation for its Series A Convertible Preferred Stock, with 98.82% of shares tendered, simplifying its capital structure.

TriSalus Life Sciences, Inc. has commenced an exchange offer and consent solicitation for its Series A Convertible Preferred Stock to simplify its capital structure and reduce potential dilution.

TriSalus Life Sciences, Inc. announced the results of its Annual Meeting of Shareholders held on June 12, 2025, where two directors were elected and Grant Thornton, LLP was ratified as the independent accounting firm for 2025.

TriSalus Life Sciences, Inc. has announced the resignation of its Chief Financial Officer, James Young, effective May 30, 2025, and the appointment of David B. Patience as his successor, effective July 1, 2025.

TriSalus Life Sciences announces strong Q1 2025 results with 42% revenue growth and updates its 2025 guidance to reflect strategic investments.

TriSalus Life Sciences secures $22 million in private placement alongside preliminary Q1 2025 results, aiming to advance its oncology-focused medical technology and simplify its capital structure.

George Kelly Martin resigned from the Board of Directors, Audit Committee, and Compensation Committee of TriSalus Life Sciences, effective immediately, on April 20, 2025.

Liselotte Hyveled resigned from TriSalus Life Sciences' Board of Directors and related committees, effective immediately, with no reported disagreements with the company.

TriSalus Life Sciences announces a 44% increase in Q4 revenue and a 59% increase in full-year revenue for 2024, alongside reaffirmed guidance for significant growth and profitability in 2025.

Sean Murphy will step down as an officer and employee of TriSalus Life Sciences, Inc. effective February 28, 2025, but will remain on the Board of Directors.

TriSalus Life Sciences, Inc. has successfully closed its second tranche of funding, receiving $10 million under its existing credit agreement.

TriSalus Life Sciences has drawn $10 million from its credit agreement with OrbiMed after achieving a $30 million product revenue milestone.

TriSalus Life Sciences appoints William Valle and Gary Gordon to its Board of Directors, increasing the board size to 11.

TriSalus Life Sciences announced preliminary unaudited results showing significant revenue growth in 2024 and expects to achieve positive EBITDA and cash flow in 2025.

TriSalus Life Sciences has announced a leadership transition, promoting James Young to CFO and appointing Sean Murphy to Chief Manufacturing, Strategy and Business Development Officer, effective January 6, 2025.

TriSalus Life Sciences announced a 42% year-over-year increase in Q3 revenue and provided optimistic guidance for 2025, including expectations for positive EBITDA and cash flow.

TriSalus Life Sciences reports the resignation of a board member and the departure of its Chief Medical Officer.

TriSalus Life Sciences announced a 60% increase in Q2 revenue and provided updates on its clinical programs, including the launch of the DELIVER program.